Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50–59 years of age, including at-increased-risk adults: A randomized controlled trial

Murdo Ferguson, Tino F. Schwarz, Sebastián A. Núñez, Juan Rodríguez-García, Marek Mital, Carlos Zala, Bonavuth Pek, Bernhard Schmitt, Nicole Toursarkissian, Dolores Ochoa Mazarro, Josef Großkopf, Christine Voors-Pette, Hemalini Mehta, Hiwot Amare Hailemariam, Catherine Gérard, Silvia Damaso, Marie-Pierre David, Dominique Descamps, Judith Hill, Corinne Vandermeulen, Veronica Hulstrøm

Open source

DOI: 10.1080/21645515.2025.2579335
Published: 12
Container: Human Vaccines & Immunotherapeutics
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/21645515.2025.2579335,
  title = {Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50–59 years of age, including at-increased-risk adults: A randomized controlled trial},
  author = {Murdo Ferguson and Tino F. Schwarz and Sebastián A. Núñez and Juan Rodríguez-García and Marek Mital and Carlos Zala and Bonavuth Pek and Bernhard Schmitt and Nicole Toursarkissian and Dolores Ochoa Mazarro and Josef Großkopf and Christine Voors-Pette and Hemalini Mehta and Hiwot Amare Hailemariam and Catherine Gérard and Silvia Damaso and Marie-Pierre David and Dominique Descamps and Judith Hill and Corinne Vandermeulen and Veronica Hulstrøm},
  year = {2025},
  journal = {Human Vaccines \& Immunotherapeutics},
  doi = {10.1080/21645515.2025.2579335},
  url = {https://doi.org/10.1080/21645515.2025.2579335}
}

RIS

TY  - JOUR
TI  - Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50–59 years of age, including at-increased-risk adults: A randomized controlled trial
AU  - Murdo Ferguson
AU  - Tino F. Schwarz
AU  - Sebastián A. Núñez
AU  - Juan Rodríguez-García
AU  - Marek Mital
AU  - Carlos Zala
AU  - Bonavuth Pek
AU  - Bernhard Schmitt
AU  - Nicole Toursarkissian
AU  - Dolores Ochoa Mazarro
AU  - Josef Großkopf
AU  - Christine Voors-Pette
AU  - Hemalini Mehta
AU  - Hiwot Amare Hailemariam
AU  - Catherine Gérard
AU  - Silvia Damaso
AU  - Marie-Pierre David
AU  - Dominique Descamps
AU  - Judith Hill
AU  - Corinne Vandermeulen
AU  - Veronica Hulstrøm
PY  - 2025
JO  - Human Vaccines & Immunotherapeutics
DO  - 10.1080/21645515.2025.2579335
UR  - https://doi.org/10.1080/21645515.2025.2579335
ER  -

APA

Ferguson, M., Schwarz, T. F., Núñez, S. A., Rodríguez-García, J., Mital, M., Zala, C., Pek, B., Schmitt, B., Toursarkissian, N., Mazarro, D. O., Großkopf, J., Voors-Pette, C., Mehta, H., Hailemariam, H. A., Gérard, C., Damaso, S., David, M., Descamps, D., Hill, J., Vandermeulen, C., & Hulstrøm, V. (2025). Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50–59 years of age, including at-increased-risk adults: A randomized controlled trial. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2025.2579335

Source records

doaj · retrieved 2026-09-26T04:46:17.192Z